Tesla
TSLA
NVIDIA
NVDA
Palantir
PLTR
4
Apple
AAPL
5
Gorilla Technology
GRRR
US Stock MarketDetailed Quotes
ALGS Aligos Therapeutics
- 10.510
- +0.100+0.96%
Close Mar 11 16:00 ET
- 10.510
- 0.0000.00%
Post 16:20 ET
64.26MMarket Cap-0.50P/E (TTM)
10.800High9.670Low153.44KVolume10.300Open10.410Pre Close1.58MTurnover3.52%Turnover RatioLossP/E (Static)6.11MShares46.80052wk High-2.22P/B45.83MFloat Cap6.76052wk Low--Dividend TTM4.36MShs Float937.748Historical High--Div YieldTTM10.85%Amplitude6.760Historical Low10.271Avg Price1Lot Size
Aligos Therapeutics Key Stats
Quarterly+Annual
YOY
| (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q4)Dec 31, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | 1.16%-20.1M | -43.16%-19.49M | -1.60%-22.75M | 0.49%-79M | -35.01%-22.66M | -18.67%-20.34M | 45.61%-13.62M | -9.56%-22.39M | 31.36%-79.39M | 55.22%-16.78M |
| Net income from continuing operations | -6.75%-19.26M | 126.93%5.06M | -51.88%-34.86M | 8.71%-87.68M | -27.44%-27.89M | 3.11%-18.04M | 5.69%-18.79M | 35.55%-22.96M | 25.16%-96.05M | 41.97%-21.89M |
| Operating gains losses | --105K | ---30.48M | --14.37M | --2.19M | --2.17M | ---- | ---- | ---- | ---- | ---- |
| Depreciation and amortization | -2.06%667K | -20.68%610K | -20.14%674K | -16.49%3.07M | -13.60%775K | -24.83%681K | -13.50%769K | -14.14%844K | -2.73%3.68M | -11.45%897K |
| Change In working capital | 48.69%-3.18M | 539.35%4.11M | -49.58%-5.49M | -513.72%-9.53M | -133.87%-293K | -118.07%-6.2M | 106.45%643K | -135.31%-3.67M | 66.63%-1.55M | 119.43%865K |
| -Change in payables and accrued expense | -12.93%-1.98M | 572.70%4M | -56.91%-4.48M | 82.46%-1.3M | -1.00%4.15M | -264.63%-1.76M | 88.49%-846K | 46.50%-2.85M | -178.67%-7.42M | -2.01%4.19M |
| -Change in other current assets | 121.82%170K | -93.63%138K | -90.22%204K | -56.79%2.3M | -105.06%-1.18M | -236.19%-779K | 9.62%2.17M | -37.58%2.09M | 165.86%5.32M | 92.67%-573K |
| -Change in other current liabilities | -21.57%-699K | -5.17%-631K | -8.90%-636K | -22.23%-2.39M | -1.46%-627K | -52.52%-575K | 34.14%-600K | -1,169.57%-584K | -18.37%-1.95M | -11.75%-618K |
| -Change in other working capital | 78.31%-671K | 896.05%605K | 74.73%-587K | -425.14%-8.14M | -23.62%-2.64M | 24.65%-3.09M | 97.94%-76K | -118.68%-2.32M | 157.40%2.5M | -482.56%-2.14M |
| Cash from discontinued investing activities | ||||||||||
| Operating cash flow | 1.16%-20.1M | -43.16%-19.49M | -1.60%-22.75M | 0.49%-79M | -35.01%-22.66M | -18.67%-20.34M | 45.61%-13.62M | -9.56%-22.39M | 31.36%-79.39M | 55.22%-16.78M |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | 115,633.33%10.4M | 59.95%39.99M | -543.37%-88.64M | 271.08%44.98M | -100.06%-7K | -100.03%-9K | 350.64%25M | 133.10%19.99M | -970.05%-26.29M | 170.42%11.6M |
| Net PPE purchase and sale | -36.84%-26K | -150.00%-7K | -885.71%-69K | 97.99%-19K | 92.31%-7K | -533.33%-19K | 104.19%14K | 98.64%-7K | -5.72%-943K | 72.92%-91K |
| Net investment purchase and sale | 104,140.00%10.42M | 60.06%40M | -542.87%-88.57M | 277.51%45M | --0 | -99.97%10K | 359.18%24.99M | 133.40%20M | -747.68%-25.35M | 172.45%11.7M |
| Cash from discontinued investing activities | ||||||||||
| Investing cash flow | 115,633.33%10.4M | 59.95%39.99M | -543.37%-88.64M | 271.08%44.98M | -100.06%-7K | -100.03%-9K | 350.64%25M | 133.10%19.99M | -970.05%-26.29M | 170.42%11.6M |
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | 80.95%-4K | -32.13%281K | -1,800.00%-19K | 53,758.54%88.33M | 72,574.38%87.94M | -10.53%-21K | 398.80%414K | 95.24%-1K | -99.79%164K | -78.08%121K |
| Net issuance payments of debt | 76.19%-5K | 65.96%-16K | 20.83%-19K | -57.38%-96K | -114.81%-4K | 25.00%-21K | -62.07%-47K | 22.58%-24K | 22.78%-61K | 235.00%27K |
| Net common stock issuance | ---- | ---- | ---- | --17.44M | ---- | ---- | ---- | ---- | --0 | ---- |
| Proceeds from stock option exercised by employees | --1K | -35.57%297K | --0 | 31,447.11%70.98M | 74,896.81%70.5M | --0 | 311.61%461K | 130.00%23K | -78.51%225K | -86.94%94K |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | 80.95%-4K | -32.13%281K | -1,800.00%-19K | 53,758.54%88.33M | 72,574.38%87.94M | -10.53%-21K | 398.80%414K | 95.24%-1K | -99.79%164K | -78.08%121K |
| Net cash flow | ||||||||||
| Beginning cash position | -50.32%45.15M | -69.18%24.37M | 66.67%135.77M | -56.43%81.46M | -18.51%70.5M | 27.64%90.87M | -25.49%79.07M | -56.43%81.46M | -15.37%186.98M | -64.01%86.52M |
| Current changes in cash | 52.34%-9.71M | 76.08%20.78M | -4,551.65%-111.41M | 151.47%54.31M | 1,390.45%65.27M | -232.88%-20.37M | 133.79%11.8M | 97.04%-2.4M | -210.69%-105.52M | 90.53%-5.06M |
| End cash Position | -49.73%35.44M | -50.32%45.15M | -69.18%24.37M | 66.67%135.77M | 66.67%135.77M | -18.51%70.5M | 27.64%90.87M | -25.49%79.07M | -56.43%81.46M | -56.43%81.46M |
| Free cash flow | 1.09%-20.13M | -43.29%-19.5M | -1.88%-22.82M | 1.64%-79.02M | -34.32%-22.67M | -18.72%-20.35M | 46.36%-13.61M | -6.90%-22.39M | 31.08%-80.33M | 55.38%-16.87M |
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | -- | -- | -- | -- | -- | -- | -- | Unqualified Opinion | -- |